Samsung Bioepis And MSD Enter Biosimilars Development And Commercialization Agreement

Samsung Bioepis Co., Ltd. and MSD, known as Merck in the United States and Canada, announced
today they have entered into an agreement to develop and commercialize multiple pre-
specified and undisclosed biosimilar candidates.

“Samsung Bioepis has been building the capabilities needed to develop high-quality
biosimilars,” said Christopher Hansung Ko,Ph.D., CEO of Samsung Bioepis. “With this
development and commercialization agreement, Samsung takes a significant step towards
becoming a major player in the biopharmaceutical industry.”

Under the agreement, Samsung Bioepis will be responsible for preclinical and clinical
development, process development and manufacturing, clinical trials and registration. MSD
will be responsible for commercialization. Samsung Bioepis will receive an upfront payment
from MSD, product supply income and will be eligible for additional payments associated
with pre-specified clinical and regulatory milestones. Further financial terms were not
disclosed.

“The combination of Merck’s global commercial presence with Samsung Bioepis’ biologic
development and manufacturing capabilities positions the two companies well to increase
access to biosimilars to improve human health,” said Rich Murray, Ph.D., senior vice
president Biologics and vaccines research at Merck. “We look forward to this collaboration
and its potential to complement our internal, expanding biologics portfolio.”

About Samsung Bioepis
Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, aims to
develop affordable and high-quality biopharmaceutical and biosimilar products. For more
information, please visit www.samsungbioepis.com

About MSD
Today's MSD is a global healthcare leader working to help the world be well. MSD is a trade
name of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through
our prescription medicines, vaccines, biologic therapies, and consumer care and animal
health products, we work with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships. For more information,
visit www.msd.com and connect with us on Twitter, Facebook and YouTube.